vs
Bandwidth Inc.（BAND）与Esperion Therapeutics, Inc.（ESPR）财务数据对比。点击上方公司名可切换其他公司
Bandwidth Inc.的季度营收约是Esperion Therapeutics, Inc.的1.2倍（$208.8M vs $168.4M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 20.1%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 9.7%）
Bandwidth Inc.是一家通信平台即服务提供商，依托自有全球IP语音网络，为客户提供语音、短信及应急服务相关的软件API产品，帮助开发者便捷集成通信功能，全球客户可借助其方案快速搭建符合需求的通信服务体系。
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
BAND vs ESPR — 直观对比
营收规模更大
BAND
是对方的1.2倍
$168.4M
营收增速更快
ESPR
高出123.6%
20.1%
两年增速更快
ESPR
近两年复合增速
9.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $208.8M | $168.4M |
| 净利润 | $4.0M | — |
| 毛利率 | 37.3% | — |
| 营业利润率 | 60.5% | 50.6% |
| 净利率 | 1.9% | — |
| 营收同比 | 20.1% | 143.7% |
| 净利润同比 | 200.0% | — |
| 每股收益（稀释后） | $-0.08 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BANDESPR
| Q1 26 | $208.8M | — | ||
| Q4 25 | $207.7M | $168.4M | ||
| Q3 25 | $191.9M | $87.3M | ||
| Q2 25 | $180.0M | $82.4M | ||
| Q1 25 | $174.2M | $65.0M | ||
| Q4 24 | $210.0M | $69.1M | ||
| Q3 24 | $193.9M | $51.6M | ||
| Q2 24 | $173.6M | $73.8M |
净利润BANDESPR
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | $-31.3M | ||
| Q2 25 | $-4.9M | $-12.7M | ||
| Q1 25 | $-3.7M | $-40.5M | ||
| Q4 24 | — | — | ||
| Q3 24 | $413.0K | $-29.5M | ||
| Q2 24 | $4.1M | $-61.9M |
毛利率BANDESPR
| Q1 26 | 37.3% | — | ||
| Q4 25 | 37.6% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 39.8% | — | ||
| Q1 25 | 41.0% | — | ||
| Q4 24 | 36.4% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 37.3% | — |
营业利润率BANDESPR
| Q1 26 | 60.5% | — | ||
| Q4 25 | -1.9% | 50.6% | ||
| Q3 25 | -1.0% | -11.4% | ||
| Q2 25 | -2.1% | 8.6% | ||
| Q1 25 | -2.7% | -34.0% | ||
| Q4 24 | -1.3% | -6.4% | ||
| Q3 24 | -0.5% | -31.0% | ||
| Q2 24 | -3.5% | 3.5% |
净利率BANDESPR
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.6% | -35.9% | ||
| Q2 25 | -2.7% | -15.4% | ||
| Q1 25 | -2.1% | -62.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.2% | -57.2% | ||
| Q2 24 | 2.3% | -83.9% |
每股收益（稀释后）BANDESPR
| Q1 26 | $-0.08 | — | ||
| Q4 25 | $-0.10 | $0.32 | ||
| Q3 25 | $-0.04 | $-0.16 | ||
| Q2 25 | $-0.16 | $-0.06 | ||
| Q1 25 | $-0.13 | $-0.21 | ||
| Q4 24 | $0.27 | $-0.14 | ||
| Q3 24 | $0.01 | $-0.15 | ||
| Q2 24 | $-0.17 | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $47.3M | $167.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $405.7M | $-302.0M |
| 总资产 | $984.2M | $465.9M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BANDESPR
| Q1 26 | $47.3M | — | ||
| Q4 25 | $111.3M | $167.9M | ||
| Q3 25 | $80.4M | $92.4M | ||
| Q2 25 | $68.1M | $86.1M | ||
| Q1 25 | $41.7M | $114.6M | ||
| Q4 24 | $83.8M | $144.8M | ||
| Q3 24 | $79.9M | $144.7M | ||
| Q2 24 | $76.4M | $189.3M |
股东权益BANDESPR
| Q1 26 | $405.7M | — | ||
| Q4 25 | $400.0M | $-302.0M | ||
| Q3 25 | $392.7M | $-451.4M | ||
| Q2 25 | $384.5M | $-433.5M | ||
| Q1 25 | $345.4M | $-426.2M | ||
| Q4 24 | $312.5M | $-388.7M | ||
| Q3 24 | $336.6M | $-370.2M | ||
| Q2 24 | $307.4M | $-344.2M |
总资产BANDESPR
| Q1 26 | $984.2M | — | ||
| Q4 25 | $1.1B | $465.9M | ||
| Q3 25 | $1.0B | $364.0M | ||
| Q2 25 | $1.0B | $347.1M | ||
| Q1 25 | $964.4M | $324.0M | ||
| Q4 24 | $989.2M | $343.8M | ||
| Q3 24 | $1.0B | $314.1M | ||
| Q2 24 | $1.0B | $352.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $45.2M |
| 自由现金流经营现金流 - 资本支出 | $-1.0M | — |
| 自由现金流率自由现金流/营收 | -0.5% | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BANDESPR
| Q1 26 | — | — | ||
| Q4 25 | $38.6M | $45.2M | ||
| Q3 25 | $22.2M | $-4.3M | ||
| Q2 25 | $31.7M | $-31.4M | ||
| Q1 25 | $-3.1M | $-22.6M | ||
| Q4 24 | $36.5M | $-35.0M | ||
| Q3 24 | $20.5M | $-35.3M | ||
| Q2 24 | $24.4M | $-7.2M |
自由现金流BANDESPR
| Q1 26 | $-1.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-35.5M | ||
| Q2 24 | — | $-7.3M |
自由现金流率BANDESPR
| Q1 26 | -0.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -68.7% | ||
| Q2 24 | — | -9.9% |
资本支出强度BANDESPR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.1% |
现金转化率BANDESPR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 49.55× | — | ||
| Q2 24 | 6.03× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BAND
暂无分部数据
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
